G13.1
Other systemic atrophy primarily affecting central nervous system in neoplastic disease
Clinical Classification Guidelines
Inclusion Terms
- Paraneoplastic limbic encephalopathy
Code First
- underlying neoplasm (C00-D49)
Medical Intelligence & Overview
Paraneoplastic limbic encephalopathy is a rare neurological condition that primarily affects the limbic system of the brain due to a paraneoplastic process. Classified under ICD-10 code G13.1, this disorder results from immune responses triggered by an underlying neoplastic disease, leading to systemic atrophy of the central nervous system. It involves inflammation and degeneration of brain tissues, which can cause various neurological symptoms. Recognizing this condition is crucial for timely diagnosis and management, especially in patients diagnosed with cancer who develop neurological changes.
Causes & Symptoms
Clinical Causes: Paraneoplastic syndrome triggered by immune response to an associated neoplasm, often a lung, breast, or testicular cancer. Autoimmune mechanisms where antibodies target neural tissues in the limbic system. Presence of specific onconeural antibodies that attack the central nervous system tissues.
Key Symptoms: Memory disturbances, particularly short-term memory loss Behavioral and personality changes, including irritability or depression Seizures due to irritation of involved brain regions Psychiatric symptoms such as hallucinations or paranoia Disorientation and confusion Anxiety and emotional instability Focal neurological deficits like weakness or sensory changes in limbs Sleep disturbances and altered consciousness in severe cases
Diagnostic & Treatment
Diagnosis Path: Neurological examination to assess cognitive and motor functions Magnetic resonance imaging (MRI) of the brain to identify inflammation or atrophy in the limbic system Detection of paraneoplastic antibodies through blood or cerebrospinal fluid tests Assessment for underlying neoplastic disease with appropriate imaging studies like CT scans or PET scans Electroencephalogram (EEG) to monitor electrical activity and detect seizure activity
Treatment Protocols: Treatment of the associated neoplasm using surgery, chemotherapy, or radiotherapy Immunotherapy options such as corticosteroids, plasmapheresis, or intravenous immunoglobulin (IVIG) Symptomatic therapies to control seizures or behavioral symptoms Supportive care including cognitive rehabilitation and psychiatric support Monitoring for disease progression or recurrence through regular follow-ups
Clinical Advice & FAQs
Billing Guidance
Is G13.1 a billable ICD-10 code?
Yes, G13.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report G13.1?
Clinical documentation must specify the nature of Other systemic atrophy primarily affecting central nervous system in neoplastic disease and any associated comorbidities for accurate reporting.
Cite this Clinical Reference